The inhibitory effect of hepatic cancer energy metabolism on immune checkpoint therapy: perspectives from single-cell multi-omics analysis
Frontiers in Immunology · 13.04.2026 · 17
DOI: 10.3389/fimmu.2026.1753670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 13.04.2026. Verfasst von Xin Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Immune Checkpoint Inhibitors, Carcinoma, Hepatocellular, Energy Metabolism. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To investigate metabolic reprogramming—especially pyruvate metabolism—in hepatocellular carcinoma (HCC) before and after immune checkpoint inhibitor (ICI) therapy, construct a metabolism-related prognostic model, and evaluate the therapeutic potential of targeting LDHA.
Methods
Integrated single-cell RNA-seq data (GEO, Mendeley) were analyzed using Seurat, AUCell, pySCENIC, CellChat, and Monocle. A prognostic model was developed from TCGA data by Cox and Lasso regression. Functional validation included in vitro CCK8 and Transwell assays in Huh7 cells and in vivo xenograft experiments combining the LDHA inhibitor (R)-GNE-140 with a PD-1 antibody.
Results
Post-ICI, HCC cells upregulated pyruvate metabolism genes (LDHA, LDHB, LDHD) but showed decreased glycolysis, lactate buildup, reduced acetylation, and suppressed TCA cycle with AMPK activation. Key transcription factors (MYC, SP5, HLF, SREBF1) were identified. CellChat revealed enhanced SPP1–CD44 and APOA1–ABCA1 signaling. Pseudotime analysis indicated terminal hepatocyte differentiation. The pyruvate metabolism-based signature predicted prognosis effectively. Combination therapy with (R)-GNE-140 and PD-1 blockade inhibited Huh7 proliferation, migration, and xenograft tumor growth without liver or renal toxicity.
Conclusion
ICI therapy induces metabolic remodeling in HCC, marked by pyruvate metabolism dysregulation and lactate accumulation, contributing to resistance. Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zitieren
APA
Li, X., Tang, L., Cao, J., & Liu, Y. (2026). The inhibitory effect of hepatic cancer energy metabolism on immune checkpoint therapy: perspectives from single-cell multi-omics analysis. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1753670
Vancouver
Li X, Tang L, Cao J, Liu Y. The inhibitory effect of hepatic cancer energy metabolism on immune checkpoint therapy: perspectives from single-cell multi-omics analysis. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1753670
BibTeX
@article{Li2026,
author = {Li, Xin and Tang, Ling and Cao, Ju and Liu, Yao},
title = {The inhibitory effect of hepatic cancer energy metabolism on immune checkpoint therapy: perspectives from single-cell multi-omics analysis},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1753670}
}
EUVIMED